Ciprofloxacine

# Ciprofloxacine ## Overview - **Classification**: Fluoroquinolone antibiotic - **Mechanism**: Inhibits bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication, transcription, repair, and recombination. This leads to bacterial cell death. ## Primary Indications 1. **Complicated Urinary Tract Infections (UTI) & Pyelonephritis** - Treatment of severe renal/urinary tract infections. 2. **Complicated Intra-abdominal Infections** - Management of infections within the abdominal cavity. 3. **Infectious Diarrhea** - Treatment for specific bacterial causes like _E. coli_ (traveler's diarrhea), _Salmonella_, _Shigella_. 4. **Anthrax (post-exposure)** - Prophylaxis and treatment for inhalational anthrax. ## Adult Dosing ### Standard Dosing **Complicated UTI & Pyelonephritis** - **Dose**: **500 mg** PO or **400 mg** IV - **Frequency**: Every 12 hours - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: 7-14 days depending on severity and pathogen **Infectious Diarrhea** - **Dose**: **500 mg** - **Frequency**: Every 12 hours - **Route**: Oral (PO) - **Duration**: 3-5 days ### Dose Adjustments - **Renal Impairment**: - CrCl 30-50 mL/min: Dose Q18h (or decrease dose by 25-50%). - CrCl <30 mL/min (including hemodialysis/CAPD): Dose Q24h (or decrease dose by 50-75%). - Administer after dialysis. - **Hepatic Impairment**: No specific dose adjustment recommended for mild to moderate impairment. Use with caution in severe impairment. - **Elderly Patients**: Monitor renal function closely; dose adjust for age-related decline in CrCl. Increased risk of tendon rupture and QT prolongation. ## Pediatric Dosing *Note: Ciprofloxacin is generally not first-line in pediatrics due to risk of arthropathy. Use is reserved for severe infections where other agents are ineffective or contraindicated (e.g., anthrax, cystic fibrosis exacerbations, multi-drug resistant infections).* ### Neonates (0-28 days) - **Dose**: **10-15 mg/kg** - **Frequency**: Every 12 hours - **Maximum**: Limited data; typically **10 mg/kg/dose**. - **Special Notes**: Use with extreme caution. Limited safety/efficacy data. Reserved for severe, life-threatening infections. Oral suspension not suitable for neonates (contains benzyl alcohol). IV route preferred. ### Infants (1-12 months) - **Dose**: **10-20 mg/kg** (e.g., for complicated UTI/pyelonephritis, anthrax) - **Frequency**: Every 12 hours - **Maximum**: **400 mg/dose** IV; **500 mg/dose** PO. - **Special Notes**: Oral suspension available. Monitor for musculoskeletal adverse effects. ### Children (1-12 years) - **Indication**: Complicated UTI/Pyelonephritis, Anthrax (post-exposure) - **Dose**: **10-20 mg/kg** - **Frequency**: Every 12 hours - **Maximum**: **400 mg/dose** IV; **750 mg/dose** PO (adult dose equivalent). - **Special Notes**: Risk of arthropathy (reversible joint damage) in weight-bearing joints. Use only when benefits outweigh risks. ### Adolescents (13-18 years) - **Dose**: Typically follows adult dosing, **250-750 mg** (PO) or **200-400 mg** (IV) - **Frequency**: Every 12 hours (some indications Q8h IV) - **Maximum**: **750 mg/dose** PO; **400 mg/dose** IV. - **Special Notes**: Monitor for adult-like adverse effects. Growth plate closure may influence risk vs. benefit. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to ciprofloxacin or other fluoroquinolones. - **Absolute**: Concomitant administration with **tizanidine** (risk of hypotension/sedation). - **Relative**: History of myasthenia gravis (may exacerbate muscle weakness). ### Common Adverse Effects - **Very Common (>10%)**: Nausea, diarrhea. - **Common (1-10%)**: Vomiting, abdominal pain, headache, dizziness, insomnia, rash. - **Serious but Rare**: Tendon rupture/tendonitis (especially Achilles), peripheral neuropathy, QT prolongation/arrhythmia, _Clostridioides difficile_ infection, dysglycemia (hypo/hyperglycemia), psychiatric effects (depression, anxiety, confusion). ### Key Drug Interactions - **Tizanidine**: **Contraindicated**. Greatly increases tizanidine levels, causing hypotension/sedation. - **Antacids, Sucralfate, Multivitamins (containing Mg, Al, Ca, Fe, Zn)**: Decreased ciprofloxacin absorption. Separate administration by at least **2-4 hours**. - **Warfarin**: Increased anticoagulant effect (elevated INR). Monitor INR closely. - **Theophylline**: Increased theophylline levels and toxicity. Monitor theophylline levels. - **NSAIDs**: Increased risk of CNS stimulation and seizures. Use with caution. - **QT-prolonging drugs (e.g., amiodarone, sotalol, tricyclic antidepressants)**: Additive QT prolongation risk. Avoid co-administration if possible. ## Monitoring & Follow-up - **Before Treatment**: Obtain culture & sensitivity, renal function (CrCl), baseline ECG (if cardiac risk factors or concomitant QT-prolonging drugs). - **During Treatment**: Monitor renal function, liver function tests (LFTs) if prolonged use. Monitor blood glucose in diabetics. - **Clinical Signs**: Watch for signs of tendon pain/swelling, new muscle weakness, tingling/numbness, severe diarrhea, rash, altered mental status, or palpitations. ## Clinical Pearls - 💡 **Tendon Rupture**: Counsel patients on the risk of tendonitis/rupture. Discontinue at first sign of pain, swelling, or inflammation. Avoid exercise. - 💡 **Administration Timing**: To minimize drug interactions, take ciprofloxacin at least **2 hours before or 6 hours after** products containing magnesium, aluminum, calcium, iron, or zinc. - 💡 **Photosensitivity**: Advise patients to avoid excessive sunlight or artificial UV light and use sun protection as cipro can cause severe phototoxic reactions. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.